| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000664A1 2-aminoalkyl-thieno[2,3-d]pyrimidines |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000660A1 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000655A1 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors |
| 01/03/2002 | WO2002000654A1 Melanocortin receptor ligands |
| 01/03/2002 | WO2002000652A1 Carbamates derived from arylalkylamines |
| 01/03/2002 | WO2002000650A2 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | WO2002000649A1 Substituted quinazoline derivatives and their use as inhibitors |
| 01/03/2002 | WO2002000647A1 Heteroaryl-phenyl substituted factor xa inhibitors |
| 01/03/2002 | WO2002000645A1 Indole derivatives useful for the treatment of cns disorders |
| 01/03/2002 | WO2002000641A2 Spla2 inhibitors |
| 01/03/2002 | WO2002000633A1 Quinolinyl and benzothiazolyl ppar-gamma modulators |
| 01/03/2002 | WO2002000632A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | WO2002000631A2 Benzhydryl derivatives |
| 01/03/2002 | WO2002000630A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | WO2002000626A1 Fused azepine derivatives and their use as antidiuretic agents |
| 01/03/2002 | WO2002000620A1 Fatty acid synthase inhibitors |
| 01/03/2002 | WO2002000612A1 Glucagon antagonists/inverse agonists |
| 01/03/2002 | WO2002000593A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | WO2002000266A2 A method of treating and preventing infectious diseases |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2002000262A2 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | WO2002000244A2 Protein mixtures for wound healing |
| 01/03/2002 | WO2002000243A2 Stabilized interleukin 2 |
| 01/03/2002 | WO2002000241A2 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide |
| 01/03/2002 | WO2002000239A1 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same |
| 01/03/2002 | WO2002000238A1 Compositions promoting alcohol metabolism |
| 01/03/2002 | WO2002000234A1 A pharmaceutical preparation of chinese herbs for preventing and treating cardiovascular and cerebrovascular disease and the use thereof |
| 01/03/2002 | WO2002000229A1 Method for the production of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross-linking in the presence of chemically non-reacting effectors of the oxygen affinity of the haemoglobin |
| 01/03/2002 | WO2002000227A2 Use of lanthanum compounds for the treatment of bone diseases |
| 01/03/2002 | WO2002000220A1 A method for treating septic shock |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000216A1 Carvedilol |
| 01/03/2002 | WO2002000213A1 Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| 01/03/2002 | WO2002000212A1 Controlled release arginine formulations |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000201A2 Method for preparing a composition |
| 01/03/2002 | WO2002000195A2 Methods and compositions for treating pain of the mucous membrane |
| 01/03/2002 | WO2002000183A2 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/03/2002 | WO2002000175A2 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | WO2002000170A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | WO2001072669A3 Therapeutic use of polyhydroxy amine derivates |
| 01/03/2002 | WO2001066564A3 Gamma-secretase inhibitors |
| 01/03/2002 | WO2001066544A3 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 01/03/2002 | WO2001062233A3 Adenosine receptor modulators |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053461A9 Multipotent neural stem cells from peripheral tissues and uses thereof |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001045836A3 Molecules derived from mechanism based drug design |
| 01/03/2002 | WO2001045689A3 Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
| 01/03/2002 | WO2001042265A3 N6 heterocyclic 8-modified adenosine derivatives |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2001028587A3 Magnetic targeted carrier |
| 01/03/2002 | WO2000061549A3 Pharmaceutical compounds |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | WO2000061146A9 Camptothecin analogs and methods of preparation thereof |
| 01/03/2002 | US20020002296 Cytoprotective Compounds |
| 01/03/2002 | US20020002191 Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor |
| 01/03/2002 | US20020002190 Antidiabetic agents increasing the expression of glucokinase (GK) to improve glucose tolerance; increase in glucose exposure coupled through GK in beta-cells to increase insulin secretion and in hepatocytes to increase glycogen deposition |
| 01/03/2002 | US20020002186 Pharmaceutical composition |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002176 Apomorphine and norapomorphine N-glucuronides, O-sulfates, O-glucuronides, N-sulfates, O-phosphates and N-phosphates, esters, ethers, and N-alkyls; sexual disorders and Parkinson's disease; bioavailability; side effect reduction |
| 01/03/2002 | US20020002174 Serotonin antagonists |
| 01/03/2002 | US20020002173 E. g., 6-(3-chlorophenyl)-1,4-dihydro-4,4-dimethyl-2H-thieno-(2,3-d)(1,3)oxazine-2 -one; agonists and antagonists of the progesterone receptor; inducing contraception and treating or preventing benign or malignant neoplastic diseases |
| 01/03/2002 | US20020002170 Piperidine and piperazine derivatives as inhibitors of the abeta fibril formation |
| 01/03/2002 | US20020002168 Heterocyclic carboxamides |
| 01/03/2002 | US20020002165 Growth hormone secretagogues useful for treatment/prevention of osteoporosis |
| 01/03/2002 | US20020002162 Synergistic methods and compositions for treating cancer |
| 01/03/2002 | US20020002161 5-HT ligands used to treat central nervous system disorders |
| 01/03/2002 | US20020002157 Salen-metal complexes having superoxide, catalase and/or peroxidase activity to treat or prevent diseases from cell or tissue damage |
| 01/03/2002 | US20020002149 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors |
| 01/03/2002 | US20020002145 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 01/03/2002 | US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 01/03/2002 | US20020002138 For use in treatment of diseases associated with reduced levels of growth hormone |
| 01/03/2002 | US20020002137 Combination of growth hormone secretagogues and antidepressants |
| 01/03/2002 | US20020002133 Stabilized granulocyte colony stimulating factor |
| 01/03/2002 | US20020001842 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/03/2002 | US20020001640 Method for improving bone modeling and chondrocyte functioning in growing canines |
| 01/03/2002 | US20020001624 Medicinal product for the promotion of wound healing |
| 01/03/2002 | US20020001600 Method of using lectins for prevention and treatment of skin diseases and disorders |
| 01/03/2002 | US20020001567 Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| 01/03/2002 | DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL |
| 01/03/2002 | DE10029371A1 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka Heterocyclic Aminoalkylpyridinderivate as psychotropic drugs |
| 01/03/2002 | DE10028204A1 Verfahren zur Auffindung von medizinisch wertvollen Wirkstoffen Method for identifying medically valuable active ingredients |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2415236A1 Novispirins: antimicrobial peptides |
| 01/03/2002 | CA2414512A1 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | CA2414409A1 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 01/03/2002 | CA2414406A1 Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/03/2002 | CA2414401A1 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | CA2414210A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | CA2414115A1 Indole derivatives useful for the treatment of cns disorders |
| 01/03/2002 | CA2413816A1 Controlled release arginine formulations |
| 01/03/2002 | CA2413702A1 Carvedilol |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413673A1 Thymic stromal lymphopoietin receptor molecules and uses thereof |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |